AI and Machine Learning in the European Pharmaceutical Industry

AYN DE JESUS | March 28, 2019

article image
Accenture reports that in 2017, the 16 top biopharmaceutical companies in the world had an aggregate global revenue of $428 billion, which was nearly half the global pharmaceutical market by net sales. The report also revealed a shift to specialty drugs for hard-to-treat diseases. AI has numerous applications in healthcare broadly, and with the help of AI in the pharmaceutical industry, global businesses and startups are collaborating to develop new treatments. Previously, we looked at AI healthcare innovations in Europe, and in this report, we specifically look at the European AI vendors that are offering machine learning solutions to pharmaceutical companies.

Spotlight

Arriello Group

We are a leading provider of Market Access Consultancy alongside Global and local Regulatory affairs and Pharmacovigilance. Headquartered in Ireland, with European operations in Central Europe, we provide expert Market Access guidance across the US, EU, LATAM, CIS, Asia and South Africa regions. With our extensive global vendor network, ISO 9001 certification, years of experience and satisfied clients, including global Originators, Biotech’s, Generics and CRO’s, no matter how complex or simple your requirements you can rely on us as a trusted partner.

OTHER ARTICLES

Artificial intelligence in pharma: utilising a valuable resource

Article | March 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 11, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | March 11, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | March 11, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Spotlight

Arriello Group

We are a leading provider of Market Access Consultancy alongside Global and local Regulatory affairs and Pharmacovigilance. Headquartered in Ireland, with European operations in Central Europe, we provide expert Market Access guidance across the US, EU, LATAM, CIS, Asia and South Africa regions. With our extensive global vendor network, ISO 9001 certification, years of experience and satisfied clients, including global Originators, Biotech’s, Generics and CRO’s, no matter how complex or simple your requirements you can rely on us as a trusted partner.

Events